133 completed, 12 recruiting, 10 terminated, 10 unknown. 184 Phase 1, 41 Phase 2.
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy UX-GIP001 - Epilepsy | Phase 1 | Not yet recruiting | Shanghai UniXell Biotechnology Co., Ltd | 12 | 2026-08-20 | 2026-07-27 |
| ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome ION337 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Ionis Pharmaceuticals, Inc. | 32 | 2026-05-21 | 2026-09-03 |
| A Study to Evaluate the Safety and Effectiveness of Magnetic Resonance-Guided Ultrasound Ablation of the Anterior Nucleus of Thalamus for the Treatment of Drug-resistant Epilepsy. MR-guided Focused Ultrasound Therapy - Epilepsy (Treatment Refractory) | Phase 1 | Not yet recruiting | Chinese PLA General Hospital | 20 | 2025-12-01 | 2025-11-25 |
| Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation nL-ATN1-001 - Dentatorubral-Pallidoluysian Atrophy | Phase 1 / Phase 2 | Active not recruiting | n-Lorem Foundation | 1 | 2025-11-06 | 2026-04-07 |
| BHV-7000 Responsive Neurostimulation System (RNS) Study BHV-700 - Epilepsy, Seizures | Phase 1 | Completed | Yale University | 5 | 2025-10-07 | 2026-10-21 |
| Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042 NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2) - Epilepsy, Alzheimer Disease | Phase 1 | Completed | NeuroPro Therapeutics, Inc. | 8 | 2025-09-29 | 2026-04-03 |
| Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. Antisense oligonucleotide treatment (ASO) - GNAO1, Epilepsy | Phase 1 / Phase 2 | Recruiting | Pirogov Russian National Research Medical University | 5 | 2025-09-09 | 2026-01-23 |
| Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies Ketogenic diet - Developmental and Epileptic Encephalopathies, Epileptic Spasms | Phase 1 | Terminated | Heather Olson | 1 | 2025-08-11 | 2026-10-14 |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients SIF001, Placebo - Epilepsy, Healthy Volunteer | Phase 1 | Recruiting | Suninflam Inc | 88 | 2025-06-16 | 2026-06-15 |
| Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ) Stiripentol capsule (Diacomit®), Stiripentol oral suspension (Diacomit®) - Dravet Syndrome, Epilepsy | Phase 1 | Completed | Biocodex | 24 | 2025-06-01 | 2025-09-16 |
| Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007 iQ-007, Placebo - Drug Resistant Epilepsy, Focal Seizure | Phase 1 | Active not recruiting | iQure Australia Pty Ltd | 72 | 2025-04-08 | 2025-12-29 |
| CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome CBD: GT4 Transdermal Delivery System - Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS) | Phase 1 / Phase 2 | Not yet recruiting | Alexander Rotenberg | 25 | 2025-01-01 | 2024-12-18 |
| A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease ION283 - Lafora Disease | Phase 1 / Phase 2 | Recruiting | Berge Minassian | 10 | 2024-12-03 | 2025-12-18 |
| Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Drug Resistant Epilepsy Single Center, Non-randomized, Phase I Clinical Trial Secretome - Epilepsy, Drugs Resistant Epilepsy | Phase 1 | Not yet recruiting | Baermed | 54 | 2024-12-01 | 2024-10-15 |
| Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy Mangafodipir, Gadolinium - Epilepsy | Phase 1 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2024-11-19 | 2026-10-29 |
| A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) NRTX-1001 - Epilepsy, Temporal Lobe | Phase 1 / Phase 2 | Recruiting | Neurona Therapeutics | 10 | 2024-11-14 | 2026-01-07 |
| Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation nL-ATN1-002 - Dentatorubral-Pallidoluysian Atrophy | Phase 1 / Phase 2 | Active not recruiting | n-Lorem Foundation | 1 | 2024-10-24 | 2026-07-13 |
| Bioequivalence Study of Two Brivaracetam Oral Solutions in Healthy Adults Under Fasting and High-Fat Meal Conditions Brivaracetam Oral Solution (Test Formulation), Brivaracetam Oral Solution (Reference Formulation) - Epilepsy (treatment Refractory) | Phase 1 | Unknown | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 60 | 2024-10-21 | 2025-01-08 |
| Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet Atorvastatin 10mg, Modification of dietary fat composition - Epilepsy, Dyslipidemia | Phase 1 / Phase 2 | Enrolling by invitation | Johns Hopkins University | 22 | 2024-10-04 | 2026-10-19 |
| A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy NaviFUS System - Drug Resistant Epilepsy, Epilepsy | Phase 1 / Phase 2 | Recruiting | NaviFUS Corporation | 8 | 2024-09-13 | 2026-09-15 |
Showing 20 of 184. Sign in to see all of them.
Seizures (20) · Drug Resistant Epilepsy (14) · Epilepsies, Myoclonic (13) · Epilepsies, Partial (10) · Lennox Gastaut Syndrome (8) · Myoclonic Epilepsies, Progressive (4) · Bipolar Disorder (3) · Central Nervous System Diseases (3) · Neuroinflammatory Diseases (3) · Spasms, Infantile (3) · Tuberous Sclerosis (3) · Alzheimer Disease (2) · Brain Injuries, Traumatic (2) · Epilepsy, Temporal Lobe (2)
Brain Diseases (184) · Nervous System Diseases (184) · Central Nervous System Diseases (181) · Pathological Conditions, Signs and Symptoms (28) · Epileptic Syndromes (27) · Signs and Symptoms (25) · Neurologic Manifestations (24) · Epilepsy, Generalized (23) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Genetic Diseases, Inborn (12) · Neoplasms (9) · Epilepsies, Myoclonic (6) · Mental Disorders (6) · Neurodegenerative Diseases (6)
eslicarbazepine acetate (30) · Lamotrigine (10) · Valproic Acid (7) · Cannabidiol (6) · Levetiracetam (6) · Oxcarbazepine (6) · brivaracetam (6) · Phenytoin (5) · perampanel (5) · Topiramate (4) · ezogabine (4) · Carbamazepine (3) · Gabapentin (3) · LY3295668 erbumine (3) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (3)
Bial - Portela C S.A. (31) · GlaxoSmithKline (14) · Children's Hospital Medical Center, Cincinnati (4) · National Institute of Neurological Disorders and Stroke (NINDS) (4) · SK Life Science, Inc. (4) · Supernus Pharmaceuticals, Inc. (4) · University of Minnesota (4) · Eli Lilly and Company (3) · Encoded Therapeutics (3) · Johns Hopkins University (3) · NeuroPro Therapeutics, Inc. (3) · UCB Biopharma SRL (3) · UCB Pharma (3) · n-Lorem Foundation (3) · Cerebral Therapeutics LLC (2)
United States (97) · Australia (10) · United Kingdom (10) · Portugal (9) · China (8) · Belgium (5) · France (5) · Germany (5) · Brazil (3) · Canada (3) · Japan (3) · South Korea (3) · Egypt (2) · India (2) · South Africa (2)
Anli Liu, MD (2) · Eric H Kossoff, MD (2) · Manuel Vaz da Silva, MD, PhD (2) · Manuel Vaz-da-Silva, MD, PhD (2) · Marc Kamin, MD (2) · Masahiro Fujita, M.D. (2) · Salvador Rico, M.D., Ph.D (2)
PMID 29063814, PMID 31048098, PMID 18778916, PMID 20887370, PMID 23642342, PMID 23798472, PMID 25377429, PMID 25912051, PMID 26030709, PMID 26710961, PMID 27012680, PMID 27350662, PMID 28500900, PMID 29749279, PMID 29933272, PMID 31333569, PMID 31624633, PMID 31672143, PMID 32190059, PMID 32395709, PMID 34119901, PMID 36859467, PMID 37770111, PMID 38932723, PMID 39331837, PMID 40650667, PMID 41249688, PMID 41780062, PMID 42647177
2018 (3), 2017 (1), 2019 (1), F31NR010645 (1), R01NS065840 (1), R01NS074409 (1), R01NS094257 (1), U54NS078059 (1)